Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis

NCT ID: NCT03219840

Last Updated: 2021-02-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-18

Study Completion Date

2018-09-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This placebo-controlled, double-blinded, randomized crossover study evaluates the plaque and gingivitis reducing capacity of Cetylpyridium Chloride (CPC) chewing gum, with mechanical oral hygiene. The study will enroll 73 students, faculty, and staff from the UTHealth School of Dentistry. Half of the eligible participants will be randomly assigned to get the CPC gum in the first treatment period (21 days), a wash-out period of 21 days, and then a placebo gum in the second treatment period (21 days). The other half will be assigned to follow the same schedule but with the treatment reversed. A statistician will perform the randomization. Primary outcomes are assessed by validated tools, such as the Plaque Index (PI), Gingival Index (GI), and percent of bleeding sites on probe (BOP).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gingivitis Plaque, Dental Periodontal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPC + Xylitol chewing gum, then Xylitol only chewing gum

Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.

Group Type EXPERIMENTAL

Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum

Intervention Type DRUG

All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.

Xylitol only chewing gum

Intervention Type DRUG

All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.

Xylitol only chewing gum, then CPC + Xylitol chewing gum

Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.

Group Type EXPERIMENTAL

Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum

Intervention Type DRUG

All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.

Xylitol only chewing gum

Intervention Type DRUG

All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum

All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.

Intervention Type DRUG

Xylitol only chewing gum

All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be aged 18 and older
* Be capable of giving informed consent themselves and are able and willing to participate in the study
* Patients willing to forgo any optional dental procedures during the study period, such as dental prophylaxis or teeth whitening
* Patients that regularly brush their teeth twice a day

Exclusion Criteria

* Pregnant or breastfeeding women
* Patients taking long-term anti-microbial or anti-inflammatory drugs
* Patients unable or unwilling to provide informed consent
* Self-reported use of tobacco products
* Gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or calculus, or soft or hard tissue tumor of the oral cavity
* Less than 26 teeth in the mouth
* Orthodontic appliances or removable partial dentures that will compromise the ability of the potential subject to participate in the study
* Periodontitis as indicated periodontal pockets greater than 5 millimeters on more than one site
* Inability to comply with assigned treatment regimen
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CONFADENT Oral Technology, Kiss Industries LLC

UNKNOWN

Sponsor Role collaborator

The University of Texas Health Science Center, Houston

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Flavia Lakschevitz, DDS, PhD

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center, Houston

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Texas Health Science Center at Houston

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSC-DB-17-0313

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microbiome Alterations With Xylitol (MAX) in Pregnancy
NCT06329596 ACTIVE_NOT_RECRUITING PHASE1/PHASE2